| Market Capitalization (Millions $) |
1,216 |
| Shares
Outstanding (Millions) |
54 |
| Employees |
76 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
628 |
| Cash Flow (TTM) (Millions $) |
-23 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Vor Biopharma Inc is a clinical-stage cell therapy company that is focused on developing and commercializing engineered hematopoietic stem cell (eHSC) therapies for the treatment of cancer. The company was founded in 2018 and is based in Cambridge, Massachusetts.
Vor Biopharma's eHSC therapies are designed to selectively target and eliminate cancer cells while preserving healthy cells. This unique approach involves modifying a patient's own stem cells to express chimeric antigen receptors (CARs) that specifically recognize and attack cancer cells. By harnessing the power of the immune system, Vor Biopharma aims to provide more effective and less toxic treatments for patients with various types of cancer.
The company's lead product candidate, VOR33, is being investigated for the treatment of acute myeloid leukemia (AML). VOR33 is designed to selectively target CD33, a protein that is highly expressed on leukemia cells. Vor Biopharma is also exploring the potential of its eHSC platform for the development of therapies for other hematologic malignancies and solid tumors.
Vor Biopharma has established collaborations with leading academic institutions and industry partners to support its research and development efforts. The company has also raised significant funding to advance its pipeline and accelerate the development of its eHSC therapies.
Overall, Vor Biopharma is dedicated to revolutionizing cancer treatment by leveraging the power of engineered stem cells to provide safe and effective therapies for patients in need.
Company Address: 500 Boylston Street Boston 2116 MA
Company Phone Number: 655-6580 Stock Exchange / Ticker: NASDAQ VOR
|
